News & Updates
Filter by Specialty:
Show Multimedia Only

Oral blarcamesine delivers long-term benefit in early AD
24 Oct 2025
byAudrey Abella
Findings from the phase IIb/III ATTENTION-AD study reflect the continued benefit of oral blarcamesine in individuals with early Alzheimer’s disease (AD) after receiving the drug continuously for up to 4 years.








